These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

840 related items for PubMed ID: 8855790

  • 21. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
    Chesnut CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ.
    Am J Med; 1997 Jan; 102(1):29-37. PubMed ID: 9209198
    [Abstract] [Full Text] [Related]

  • 26. Relationship between dental panoramic radiographic findings and biochemical markers of bone turnover.
    Taguchi A, Sanada M, Krall E, Nakamoto T, Ohtsuka M, Suei Y, Tanimoto K, Kodama I, Tsuda M, Ohama K.
    J Bone Miner Res; 2003 Sep; 18(9):1689-94. PubMed ID: 12968679
    [Abstract] [Full Text] [Related]

  • 27. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
    Yamazaki S, Ichimura S, Iwamoto J, Takeda T, Toyama Y.
    J Bone Miner Metab; 2004 Sep; 22(5):500-8. PubMed ID: 15316873
    [Abstract] [Full Text] [Related]

  • 28. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
    Verit FF, Geyikli I, Yazgan P, Celik A.
    Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
    [Abstract] [Full Text] [Related]

  • 29. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 30. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A, Glover SJ, Eastell R.
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [Abstract] [Full Text] [Related]

  • 31. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 Dec; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 32. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [Abstract] [Full Text] [Related]

  • 33. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS.
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [Abstract] [Full Text] [Related]

  • 34. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
    Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D.
    Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
    [Abstract] [Full Text] [Related]

  • 35. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women.
    Pereda CA, Hannon RA, Naylor KE, Eastell R.
    BJOG; 2002 Jul; 109(7):812-20. PubMed ID: 12135219
    [Abstract] [Full Text] [Related]

  • 36. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation.
    Avbersek-Luznik I, Gmeiner Stopar T, Marc J.
    Clin Chem Lab Med; 2007 Jul; 45(8):1014-8. PubMed ID: 17579570
    [Abstract] [Full Text] [Related]

  • 37. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD.
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [Abstract] [Full Text] [Related]

  • 38. Relationship of bone turnover to bone density and fractures.
    Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL.
    J Bone Miner Res; 1997 Jul; 12(7):1083-91. PubMed ID: 9200008
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements.
    Akin O, Göl K, Aktürk M, Erkaya S.
    Gynecol Endocrinol; 2003 Feb; 17(1):19-29. PubMed ID: 12724015
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
    Rosen HN, Parker RA, Greenspan SL, Iloputaife ID, Bookman L, Chapin D, Perlmutter I, Kessel B, Qvist P, Rosenblatt M.
    Calcif Tissue Int; 2004 May; 74(5):415-23. PubMed ID: 14961215
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.